Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 851387, 16 pages
http://dx.doi.org/10.1155/2015/851387
Review Article

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

1Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, 9 Sklodowskiej-Curie Street, 85-094 Bydgoszcz, Poland
2Department of Cardiology and Internal Medicine, Faculty of Medicine, Nicolaus Copernicus University in Toruń, 9 Sklodowskiej-Curie Street, 85-094 Bydgoszcz, Poland

Received 22 March 2015; Accepted 19 May 2015

Academic Editor: Jean Kanitakis

Copyright © 2015 Anna Niezgoda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. DeSantis, C. C. Lin, A. B. Mariotto et al., “Cancer treatment and survivorship statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 4, pp. 252–271, 2014. View at Publisher · View at Google Scholar
  2. WHO, Ultraviolet Radiation and the INTERSUN Programme, WHO, 2009.
  3. American Cancer Society, Cancer Fact and Figures 2015, American Cancer Society, 2015.
  4. N. Howlader, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2010, National Cancer Institute, 2013.
  5. National Cancer Institute, Melanoma Treatment (PDQ), National Cancer Institue, 2014.
  6. J. M. Junkins-Hopkins, “Malignant melanoma: molecular cytogenetics and their implications in clinical medicine,” Journal of the American Academy of Dermatology, vol. 63, no. 2, pp. 329–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Ramnath and A. Adjei, “Inhibitors of Raf kinase and MEK signaling,” Update on Cancer Therapeutics, vol. 2, no. 3, pp. 111–118, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Vultur, J. Villanueva, and M. Herlyn, “Targeting BRAF in advanced melanoma: a first step toward manageable disease,” Clinical Cancer Research, vol. 17, no. 7, pp. 1658–1663, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Wellbrock and A. Hurlstone, “BRAF as therapeutic target in melanoma,” Biochemical Pharmacology, vol. 80, no. 5, pp. 561–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Shah and R. S. Dronca, “Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma,” Mayo Clinic Proceedings, vol. 89, no. 4, pp. 504–519, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-T. Arkenau, R. Kefford, and G. V. Long, “Targeting BRAF for patients with melanoma,” British Journal of Cancer, vol. 104, no. 3, pp. 392–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. S. Inumaru, K. I. F. Gordo, A. C. Fraga Jr. et al., “Analysis of the BRAF V600E mutation in primary cutaneous melanoma,” Genetics and Molecular Research, vol. 13, no. 2, pp. 2840–2848, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. P. A. Ascierto, J. M. Kirkwood, J.-J. Grob et al., “The role of BRAF V600 mutation in melanoma,” Journal of Translational Medicine, vol. 10, no. 1, article 85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Omholt, D. Kröckel, U. Ringborg, and J. Hansson, “Mutations of PIK3CA are rare in cutaneous melanoma,” Melanoma Research, vol. 16, no. 2, pp. 197–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Swaika, J. A. Crozier, and R. W. Joseph, “Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma,” Drug Design, Development and Therapy, vol. 8, pp. 775–787, 2014. View at Publisher · View at Google Scholar
  17. J. A. Sosman, K. B. Kim, L. Schuchter et al., “Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib,” The New England Journal of Medicine, vol. 366, no. 8, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G. A. McArthur, P. B. Chapman, C. Robert et al., “Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study,” The Lancet Oncology, vol. 15, no. 3, pp. 323–332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. A. Ascierto, D. Minor, A. Ribas et al., “Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3205–3211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Menzies, G. V. Long, and R. Murali, “Dabrafenib and its potential for the treatment of metastatic melanoma,” Drug Design, Development and Therapy, vol. 6, pp. 391–405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Hauschild, J.-J. Grob, L. V. Demidov et al., “Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial,” The Lancet, vol. 380, no. 9839, pp. 358–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Robert, K. T. Flaherty, P. Hersey et al., “METRIC phase III study: efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (PTS) with BRAFV600E/K mutant advanced or metastatic melanoma (MM),” Journal of Clinical Oncology, vol. 30, no. 18, 2012. View at Google Scholar
  24. GlaxoSmithKline, “Dabrafenib plus trametinib vs vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma (COMBI-v),” ClinicalTrials.gov NCT01597908, 2014. View at Google Scholar
  25. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. F. S. Hodi, S. Lee, D. F. McDermott et al., “Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial,” The Journal of the American Medical Association, vol. 312, no. 17, pp. 1744–1753, 2014. View at Publisher · View at Google Scholar
  28. L. H. Camacho, S. Antonia, J. Sosman et al., “Phase I/II trial of tremelimumab in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1075–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Ribas, R. Kefford, M. A. Marshall et al., “Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma,” Journal of Clinical Oncology, vol. 31, no. 5, pp. 616–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Yamazaki, H. Tahara, H. Uhara et al., “Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma,” European Journal of Cancer, vol. 49, p. s868, 2013. View at Google Scholar
  31. C. Robert, G. V. Long, B. Brady et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal Of Medicine, vol. 372, no. 4, pp. 320–330, 2014. View at Publisher · View at Google Scholar
  32. T. K. Burki, “Lambrolizumab induces advanced melanoma regression,” The Lancet Oncology, vol. 14, no. 8, p. E297, 2013. View at Publisher · View at Google Scholar
  33. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Bagcchi, “Pembrolizumab for treatment of refractory melanoma,” The Lancet Oncology, vol. 15, no. 10, article e419, 2014. View at Publisher · View at Google Scholar
  35. M. B. Atkins, R. R. Kudchadkar, M. Sznol et al., “Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 32, supplement, abstract 9001, 2014. View at Google Scholar
  36. A. M. Menzies and G. V. Long, “Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond,” European Journal of Cancer, vol. 49, no. 15, pp. 3229–3241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity,” Current Opinion in Immunology, vol. 24, no. 2, pp. 207–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Ribas, “Tumor immunotherapy directed at PD-1,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2517–2519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. P. B. Chapman, A. Hauschild, C. Robert et al., “Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma,” Journal of Clinical Oncology, vol. 30, abstract 8502, 2012, ASCO Annual Meeting. View at Google Scholar
  40. GlaxoSmithKline, Highlights of Prescribing Information of Tafinlar (Dabrafenib Capsules), GlaxoSmithKline, Brentford, UK, 2014.
  41. GlaxoSmithKline, Two New GSK Oral Oncology Treatments, BRAF-Inhibitor Tafinlar (Dabrafenib) Capsules and the First MEK-Inhibitor Mekinist (Trametinib) Tablets, Approved by FDA as Single-Agent Therapies, GlaxoSmithKline, 2014.
  42. G. S. Falchook, G. V. Long, R. Kurzrock et al., “Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial,” The Lancet, vol. 379, no. 9829, pp. 1893–1901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. G. V. Long, U. Trefzer, M. A. Davies et al., “Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 11, pp. 1087–1095, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Lemech, J. Infante, and H.-T. Arkenau, “Combination molecularly targeted drug therapy in metastatic melanoma: progress to date,” Drugs, vol. 73, no. 8, pp. 767–777, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. M. Menzies and G. V. Long, “New combinations and immunotherapies for melanoma: latest evidence and clinical utility,” Therapeutic Advances in Medical Oncology, vol. 5, no. 5, pp. 278–285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. V. A. Trinh, Y. You, and W.-J. Hwu, “Treatment of BRAF-mutated advanced cutaneous melanoma,” Chinese Clinical Oncology, vol. 3, no. 3, 2014. View at Google Scholar
  47. Novartis Pharmaceuticals, “Study comparing combination of LGX818 plus MEK162 and LGX818 monotherapy versus vemurafenib in BRAF mutant melanoma (COLUMBUS),” ClinicalTrials.gov NCT01909453, 2015. View at Google Scholar
  48. R. J. Sullivan and K. T. Flaherty, “Resistance to BRAF-targeted therapy in melanoma,” European Journal of Cancer, vol. 49, no. 6, pp. 1297–1304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. E. R. Sauter, U.-C. Yeo, A. von Stemm et al., “Cyclin D1 is a candidate oncogene in cutaneous melanoma,” Cancer Research, vol. 62, no. 11, pp. 3200–3206, 2002. View at Google Scholar · View at Scopus
  50. K. H. T. Paraiso, Y. Xiang, V. W. Rebecca et al., “PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression,” Cancer Research, vol. 71, no. 7, pp. 2750–2760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. K. L. Nathanson, A.-M. Martin, B. Wubbenhorst et al., “Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436),” Clinical Cancer Research, vol. 19, no. 17, pp. 4868–4878, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. T. R. Wilson, J. Fridlyand, Y. Yan et al., “Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors,” Nature, vol. 487, no. 7408, pp. 505–509, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. P. I. Poulikakos, Y. Persaud, M. Janakiraman et al., “RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E),” Nature, vol. 480, no. 7377, pp. 387–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Shi, G. Moriceau, X. Kong et al., “Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance,” Nature Communications, vol. 3, article 724, 16 pages, 2012. View at Publisher · View at Google Scholar
  55. National Cancer Institute, “Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma,” ClinicalTrials.gov NCT02224781, 2014. View at Google Scholar
  56. C. J. M. Wright and P. L. McCormack, “Trametinib: first global approval,” Drugs, vol. 73, no. 11, pp. 1245–1254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. K. T. Flaherty, C. Robert, P. Hersey et al., “Improved survival with MEK inhibition in BRAF-mutated melanoma,” The New England Journal of Medicine, vol. 367, no. 2, pp. 107–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. N. K. Haass, K. Sproesser, T. K. Nguyen et al., “The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel,” Clinical Cancer Research, vol. 14, no. 1, pp. 230–239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. B. R. Davies, A. Logie, M. Cockerill et al., “AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models,” Molecular Cancer Therapeutics, vol. 6, no. 8, pp. 2209–2219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Huynh, P. K. H. Chow, and K.-C. Soo, “AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma,” Molecular Cancer Therapeutics, vol. 6, no. 9, pp. 2468–2476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. S. V. Holt, A. Logié, R. Odedra et al., “The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models,” British Journal of Cancer, vol. 106, no. 5, pp. 858–866, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. J. M. Kirkwood, L. Bastholt, C. Robert et al., “Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma,” Clinical Cancer Research, vol. 18, no. 2, pp. 555–567, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Robert, R. Dummer, R. Gutzmer et al., “Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study,” The Lancet Oncology, vol. 14, no. 8, pp. 733–740, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Larkin, P. A. Ascierto, B. Dréno et al., “Combined vemurafenib and cobimetinib in BRAF-mutated melanoma,” The New England Journal of Medicine, vol. 371, no. 20, pp. 1867–1876, 2014. View at Publisher · View at Google Scholar
  65. Melanoma Research Foundation Breakthrough Consortium, “Trial of vemurafenib/cobimetinib with or without bevacizumab in patients with stage IV BRAFV600 mutant melanoma,” ClinicalTrials.gov NCT01495988, 2014. View at Google Scholar
  66. Sunnybrook Health Sciences Centre, “Study of neo-adjuvant use of vemurafenib plus cobimetinib for BRAF mutant melanoma with palpable lymph node metastases,” ClinicalTrials.gov NCT02036086, 2014. View at Google Scholar
  67. H. Tawbi, “Phase II study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (CoBRIM-B),” ClinicalTrials.gov NCT02230306, 2015. View at Google Scholar
  68. University Hospital Tuebingen, “Neoadjuvant vemurafenib + cobimetinib in melanoma: NEO-VC,” ClinicalTrials.gov NCT02303951, 2014. View at Google Scholar
  69. Genentech, “A phase 1b study of MPDL3280A (an engineered anti-PDL1 antibody) in combination with vemurafenib (zelboraf) or vemurafenib plus cobimetinib in patients with previously untreated BRAFV600-mutation positive metastatic melanoma,” ClinicalTrials.gov NCT01656642, 2015. View at Google Scholar
  70. P. A. Ascierto, D. Schadendorf, C. Berking et al., “MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study,” The Lancet Oncology, vol. 14, no. 3, pp. 249–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. K. T. Flaherty, J. R. Infante, A. Daud et al., “Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations,” The New England Journal of Medicine, vol. 367, no. 18, pp. 1694–1703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. US Food and Drug Administration, Trametinib and Dabrafenib, US Food and Drug Administration, 2014.
  73. B. Neyns, “Dabrafenib and Trametinib for BRAF-inhibitor pretreated patients,” ClinicalTrials.gov NCT02296996, 2014. View at Google Scholar
  74. GlaxoSmithKline, “A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD),” ClinicalTrials.gov NCT01682083, 2014. View at Google Scholar
  75. MD Anderson Cancer Center, “Combi-neo study for stage IV melanoma,” ClinicalTrials.gov NCT02231775, 2015. View at Google Scholar
  76. J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian, “Somatic activation of KIT in distinct subtypes of melanoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4340–4346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Guo, L. Si, Y. Kong et al., “Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification,” Journal of Clinical Oncology, vol. 29, no. 21, pp. 2904–2909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Lee, “Study of nilotinib in metastatic melanoma with KIT aberrations,” ClinicalTrials.gov NCT01099514, 2014. View at Google Scholar
  79. AB Science, “A phase 3 study to compare efficacy and safety of masitinib to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the Juxta membrane domain of C-kit,” ClinicalTrials.gov NCT01280565, 2012. View at Google Scholar
  80. C. Roddie and K. S. Peggs, “Emerging options for the treatment of melanoma—focus on ipilimumab,” ImmunoTargets & Therapy, vol. 3, pp. 67–78, 2014. View at Publisher · View at Google Scholar
  81. K. A. Lyseng-Williamson, “Ipilimumab: a guide to its use in advanced melanoma in the EU,” Drugs & Therapy Perspectives, vol. 30, no. 4, pp. 124–129, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Margolin, M. S. Ernstoff, O. Hamid et al., “Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 5, pp. 459–465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. L. E. Spitler, “Granulocyte macrophage-colony stimulating factor and ipilimumab as therapy in melanoma (GIPI),” ClinicalTrials.gov NCT01363206, 2014. View at Google Scholar
  84. F. S. Hodi, “Bevacizumab plus ipilimumab in patients with unresectable stage III or IV melanoma,” ClinicalTrials.gov NCT00790010, 2014. View at Google Scholar
  85. US Food and Drug Administration, FDA Approves Opdivo for Advanced Melanoma, US Food and Drug Administration, 2014.
  86. J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. B.-M. Squibb, “Phase 3 study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma,” ClinicalTrials.gov NCT01844505, 2015. View at Google Scholar
  88. National Cancer Institute, “Nivolumab and ipilimumab with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery,” ClinicalTrials.gov NCT02339571, 2015. View at Google Scholar
  89. Merck Sharp & Dohme Corporation, “Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma,” ClinicalTrials.gov NCT01295827, 2015. View at Google Scholar
  90. M. Sharp and D. Corp, “Study of pembrolizumab (MK-3475) versus chemotherapy in participants with advanced melanoma,” ClinicalTrials.gov NCT01704287, 2015. View at Google Scholar
  91. U.S. Food and Drug Administration, Pembrolizumab, U.S. Food and Drug Administration, 2014.
  92. O. Hamid, J. A. Sosman, D. P. Lawrence et al., “Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PDL1 antibody in patients with locally advanced or metastatic melanoma,” Journal Clinical Oncology, vol. 31, abstract 9010, 2013. View at Google Scholar
  93. Genentech, “A phase 1 study of MPDL3280A (an engineered anti-PDL1 antibody) in patients with locally advanced or metastatic solid tumors,” ClinicalTrials.gov NCT01375842, 2014. View at Google Scholar
  94. H.-L. Roche, “A study to assess the safety and tolerability of MPDL3280A in combination with other immune modulating therapies in patients with locally advanced or metastatic solid tumors,” ClinicalTrials.gov NCT02174172, 2015. View at Google Scholar
  95. J. R. Brahmer, S. S. Tykodi, S. L. Topalian et al., “Safety and activity of anti–PD-L1 antibody in patients with advanced cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2455–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. MedImmune, “A phase 1/2 study to evaluate MEDI4736,” ClinicalTrials.gov NCT01693562, 2015. View at Google Scholar
  97. Ludwig Institute for Cancer Research, “A phase 1 study to evaluate MEDI4736 in combination with tremelimumab,” ClinicalTrials.gov NCT01975831, 2014. View at Google Scholar
  98. C. R. Heery, G. H. O'Sullivan Coyne, R. A. Madan et al., “Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies,” Journal Clinical Oncology, vol. 32, supplement, abstract 3064, 2014. View at Google Scholar
  99. J. R. Infante, J. D. Powderly, H. A. Burris et al., “Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor,” Journal Clinical Oncology, vol. 31, supplement, abstract 3044, 2014. View at Google Scholar
  100. Amplimmune, “Study to assess the safety, tolerability, and pharmacokinetics of AMP-224 in patients with advanced cancer,” ClinicalTrials.gov NCT01352884, 2014. View at Google Scholar